title: Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection-site sarcoma: results in 21 cats.
abstract: This study assesses the outcome of two combined treatment strategies for the treatment of feline injection-site sarcoma (FISS). Twenty-one cats with primary or recurrent FISS received 3 cycles of neoadjuvant chemotherapy with epirubicin (25 mg m(-2) ), then an anatomical resection of the entire muscle compartment containing the tumour was performed based on the findings of co-axial imaging. Cats then received a further 3 cycles of adjuvant chemotherapy. Follow-up was performed by telephone contact with a median follow-up time of 1072 days. Three cats (14%) developed local tumour recurrence at days 264, 664 and 1573 after surgery. A median survival time could not be calculated as over 80% of the study population remained alive or were censored due to death from other causes. When compared to historical controls, the results of this study demonstrate superior rates of tumour-free survival and disease-free interval.
authors: Veterinary Teaching Hospital, Massey University, Palmerston North, New Zealand.
authors: J
authors: J
authors: Bray
authors: North Downs Specialist Referrals, Bletchingley, UK.
authors: G
authors: G
authors: Polton
mesh_terms: D000818:Animals; D002371:Cat Diseases / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D002415:Cats; D017024:Chemotherapy, Adjuvant / Q000662:veterinary*; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections / Q000009:adverse effects / Q000662:veterinary*; D020360:Neoadjuvant Therapy / Q000662:veterinary*; D012509:Sarcoma / Q000209:etiology / Q000628:therapy / Q000662:veterinary*
chemical_list: D015251:Epirubicin
keywords: injection site; neoadjuvant; sarcoma; surgery